Enterprise Value
2.074B
Cash
336.6M
Avg Qtr Burn
-25.33M
Short % of Float
11.40%
Insider Ownership
1.16%
Institutional Own.
89.82%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Orladeyo (Berotralstat) Details Rare diseases, Rare genetic disease, Hereditary angioedema | Approved Quarterly sales | |
Rapivab (peramivir) Details Influenza | Approved Quarterly sales | |
BCX10013 (Oral Factor D inhibitor) Details Complement mediated diseases, Paroxysmal nocturnal hemoglobinuria | Phase 1 Update | |
BCX9250 (ALK2 inhibitor) Details Fibrodysplasia ossificans progressiva | Failed Discontinued | |
Galidesivir (BCX4430) Details COVID-19 | Failed Discontinued | |
BCX9930 (Oral Factor D inhibitor) Details Paroxysmal nocturnal hemoglobinuria | Failed Discontinued |